Clinical and Translational

Better Knowledge for Better Care with QIAGEN and N-of-One: Precision medicine for any cancer assay on any platform

555 views
May 29, 2019
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences. QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000). N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests. Join us for an informative webinar about both clinical interpretation solutions.

Interested in learning more?

Click here


Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less

Related videos

Clinical and Translational

Managing Multiple Biomarker Therapeutic Development

153 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...

Clinical and Translational

How to reduce your test turnaround for large panels in molecular oncology

85 views December 31, 2019

Speaker: Sheryl Elkin, CSO, N-of-One.a QIAGEN Company Interested in learning...

Clinical and Translational

LeukoVantage: A Quest/Qiagen Partnership Providing Clinical Insights Into Myeloid Malignancies

91 views December 09, 2019

The integration of next-generation sequencing (NGS) into the diagnostic...

Clinical and Translational

Cancer Gene Variant Detection Using a Pre-Optimized Sample to Report Workflow

100 views October 30, 2019

BRCA1/BRCA2 genes represent the best examples for our current understanding...